Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Similarity of AK104 From New vs Original Manufacturing Site in Healthy Males
NCT07619001Phase 1Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jun 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised trial of cadonilimab in cancer (2 arms), sponsored by Akeso, Inc. Primary endpoint: Area under the plasma concentration-time curve from time zero to infinity at Day 22. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07619001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619001.